| Outcome Measures: |
Primary: AEs/serious AEs (SAEs), Incidence and severity of adverse event, Throughout study duration, up to 9 weeks|Percentage of subjects with clinically significant change from baseline in vital signs, Throughout study duration, up to 9 weeks|Percentage of subjects with clinically significant change from baseline in electrocardiogram (ECG), Throughout study duration, up to 9 weeks|Percentage of subejcts with clinically significant change from baseline in safety laboratory test results, Throughout study duration, up to 9 weeks | Secondary: Maximum concentration of IDG-16177(Cmax), Throughout study duration, up to 9 weeks|Time of maximum plasma IDG-16177 concentration (Tmax), Throughout study duration, up to 9 weeks|Area under the concentration-time curve (AUC), Throughout study duration, up to 9 weeks|Terminal elimination rate constant (λz), Throughout study duration, up to 9 weeks|Terminal elimination half-life calculated as: ln2/λz (T½), Throughout study duration, up to 9 weeks|Apparent total clearance of the drug from plasma after oral administration (CL/F), Throughout study duration, up to 9 weeks|Cumulative urinary excretion from time 0 to time t (Ae0-t), Throughout study duration, up to 9 weeks|Renal clearance of the drug from plasma (CLR), Throughout study duration, up to 9 weeks|Accumulation ratio (Rac), Throughout study duration, up to 9 weeks|Apparent volume of distribution following oral administration (Vd/F), Throughout study duration, up to 9 weeks | Other: Insulin, plasma concentration, Through the treatment; Plasma concentration will be observed at baseline and 0.25, 0.5, 1, 1.5, 2, 3 and 4 hours after dose|proinsulin, plasma concentration, Through the treatment; Plasma concentration will be observed at baseline and 0.25, 0.5, 1, 1.5, 2, 3 and 4 hours after dose|C-peptide, plasma concentration, Through the treatment; Plasma concentration will be observed at baseline and 0.25, 0.5, 1, 1.5, 2, 3 and 4 hours after dose|Glucagon, plasma concentration, Through the treatment; Plasma concentration will be observed at baseline and 0.25, 0.5, 1, 1.5, 2, 3 and 4 hours after dose|Glucose, plasma concentration, Through the treatment; Plasma concentration will be observed at baseline and 0.25, 0.5, 1, 1.5, 2, 3 and 4 hours after dose|HbA1c level, Change from baseline in HbA1c level, Through the treatment; Days 8, 15 and 28
|
